Oncothyreon Inc. ( ONTY ) was a big mover last session, as the company saw its shares rise a little over 5% on the day. This rise can be attributable to solid volume too with far more shares changing hands than in a normal session. This continues the most recent uptrend of the company, as the stock is now up 14.04% in the past one-month time frame.
In the last 30 days, the company witnessed 2 upward and downward estimate revisions each while the Zacks Consensus Estimate has remained unchanged in the same period. However, the recent price action is encouraging, so make sure to keep a close watch on this firm in the near future.
Oncothyreon currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Some better-ranked biopharmaceutical stocks include Heska Corporation ( HSKA ), Actelion Ltd. ( ALIOF ) and AMAG Pharmaceuticals, Inc. ( AMAG ). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
ACTELION LTD (ALIOF): Get Free Report
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
ONCOTHYREON INC (ONTY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research